Ibutamoren

Drug Profile

Ibutamoren

Alternative Names: Ibutamoren mesilate; Ibutamoren mesylate; L 163191; MK-0677; MK-677; Oratrope™

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Ammonett Pharma; Merck & Co
  • Class Indoles; Small molecules; Spiro compounds
  • Mechanism of Action Growth hormone releasing factor agonists; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Somatotropin deficiency
  • No development reported Fibromyalgia; Muscular atrophy
  • Discontinued Alzheimer's disease; Fracture; Postmenopausal osteoporosis

Most Recent Events

  • 19 Jun 2017 Ibutamoren receives Orphan Drug status for Somatotropin deficiency (In children) in USA
  • 25 May 2017 Ammonett Pharma receives Notice of allowance for ibutamoren in USA
  • 25 May 2017 Preclinical trials in Somatotropin deficiency (In children) in USA (PO) before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top